15. C. J. Powers, K. Früh, PLoS Pathog. 4, e1000150
(2008).
16. R. S. Tirabassi, H. L. Ploegh, J. Virol. 76, 6832
(2002).
17. M. H. Furman, N. Dey, D. Tortorella, H. L. Ploegh, J. Virol.
76, 11753 (2002).
18. C. Powers, V. DeFilippis, D. Malouli, K. Früh, Curr. Top.
Microbiol. Immunol. 325, 333 (2008).
19. A. Krmpotic et al., J. Exp. Med. 190, 1285 (1999).
20. L. K. Selin et al., Immunol. Rev. 211, 164 (2006).
21. R. F. Pass et al., N. Engl. J. Med. 360, 1191 (2009).
22. We are grateful to P. Barry for providing the
RhCMV-GFP and RhCMV-BAC and M. Messerle for
plasmid ori6k-F5. The NIH Nonhuman Primate Reagent
Resource Program provided the CD8a-specific antibody
cM-T807 used in this work (contracts AI040101 and
RR016001), which was originally obtained from
Centocor, Inc. We thank A. Townsend for help with
the graphics. We thank D. Drummond, L. Coyne-Johnson,
M. Spooner Lewis, C. Hughes, N. Whizin, M. Giday,
J. Clock, J. Cook, J. Edgar, J. Dewane, and A. Legasse
for technical assistance. This research was supported
by the National Institutes of Health (RO1 AI059457
to K.F. and RO1 AI060392 to L.J.P.), the International
AIDS Vaccine Initiative (to L.J.P.), the National Center
for Research Resources (RR016025 and RR18107 to
M.K.A.; RR00163 supporting the Oregon National
Primate Research Center), the Ruth L. Kirschstein
National Research Service Awards T32 AI007472 (to
C.J.P.) and T32 HL007781 (to R.R.), the OHSU Tartar
Trust fellowship (to C.J.P.), and the Achievement
Reward for College Scientists (to R.R.). The CMV vector
technology has been patented by Oregon Health and
Science University (US2008/0199493A1) with L.J.P.,
J.A.N., and M.A.J. as coinventors. This patent has been
licensed to the International AIDS Vaccine Initiative.
The comparative genome sequencing data shown in
fig. S5 were deposited in the Gene Expression Omnibus
database (accession number GSE20308).
